▲ Peaking
Business
All eyes on data on Biogen’s tau therapy
Biogen’s experimental anti-tau therapy, Diranersen, reports slowed cognitive decline in early Alzheimer's disease patients during Phase 2 clinical trials.
Aaic
1 trends tracked about this subject — the full history, oldest to newest below.